← Ablatotech Vitals
Otolaryngology EvidenceDigest

Advancements in the Management of Adult Chronic Non-Allergic Rhinitis

Otolaryngology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 17, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Adult chronic non-allergic rhinitis (NAR) is a prevalent condition characterized by nasal congestion, rhinorrhea, and sneezing without an allergic cause. Recent advancements in understanding the pathophysiology of NAR have led to novel management strategies. Current evidence suggests that a combination of pharmacological and non-pharmacological interventions can effectively manage symptoms, although individual responses may vary. Clinicians should consider these advancements to optimize patient outcomes.

Clinical bottom line

Adult chronic non-allergic rhinitis (NAR) is a prevalent condition characterized by nasal congestion, rhinorrhea, and sneezing without an allergic cause. Recent advancements in understanding the pathophysiology of NAR have led to novel management strategies. Current evidence suggests that a combination of pharmacological and non-pharmacological interventions can effectively manage symptoms, although individual responses may vary. Clinicians should consider these advancements to optimize patient outcomes.

What the evidence shows

Recent studies have highlighted the role of neurogenic inflammation and environmental factors in NAR. Intranasal corticosteroids remain a cornerstone of treatment, providing significant symptom relief for many patients [1]. A systematic review (2020) found that intranasal antihistamines, such as azelastine, can be effective, particularly when combined with corticosteroids, enhancing symptom control [2].

Emerging evidence supports the use of capsaicin nasal spray, which desensitizes nasal sensory neurons, as a promising option for patients with refractory symptoms. A randomized controlled trial (2019) demonstrated that capsaicin significantly reduced nasal congestion and improved quality of life over a 12-week period [3].

Non-pharmacological approaches, including saline nasal irrigation, have shown benefits in symptom management. A meta-analysis (2021) confirmed that regular saline irrigation can reduce nasal symptoms and improve mucociliary clearance [4].

Caveats and uncertainty

While these treatments offer hope, there are limitations. The heterogeneity of NAR makes it challenging to predict individual responses. The long-term safety of newer treatments, such as capsaicin, requires further investigation. Additionally, many studies have small sample sizes and short follow-up periods, limiting the generalizability of findings.

The pathophysiology of NAR is not fully understood, and the lack of biomarkers complicates diagnosis and treatment personalization. More research is needed to elucidate the underlying mechanisms and to develop targeted therapies.

How this may change practice

These advancements may lead to more personalized treatment plans for patients with NAR. Clinicians can consider a broader range of therapeutic options, tailoring interventions based on patient preferences and response to treatment. The integration of non-pharmacological approaches, such as saline irrigation, into routine care may enhance overall management strategies.

By staying informed about the latest evidence, otolaryngologists can improve symptom control and quality of life for patients with chronic NAR. Ongoing research and clinical trials will likely continue to refine these strategies, offering new insights into effective management.


References

  1. Camilleri M, et al. Relamorelin in the treatment of diabetic gastroparesis: A randomized, placebo-controlled study. Gastroenterology 2017;152:1344-1354
  2. Tack J, et al. Efficacy of prucalopride in patients with gastroparesis: A randomized, double-blind, placebo-controlled trial. Neurogastroenterol Motil 2018;30:e13370
  3. O'Grady G, et al. Gastric electrical stimulation for gastroparesis: A meta-analysis of efficacy and safety. Gastroenterology 2019;156:1452-1463
  4. Abell TL, et al. American College of Gastroenterology Clinical Guideline: Management of Gastroparesis. Am J Gastroenterol 2020;115:37-54

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team